CHATSWORTH, Calif., Oct. 22, 2009 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that Chief Financial Officer, Peter L. Donato, will present an overview of the Company at The Oppenheimer 20th Annual Healthcare Conference on Tuesday, November 3, 2009, at 1:00 p.m. Eastern time at the Waldorf Astoria Hotel in New York City.
A webcast of Mr. Donato's presentation will be available live and by replay. To access the live webcast, go to http://www.veracast.com/webcasts/opco/healthcare09/63108573.cfm. The link will also be available on the Investor Relations page of the IRIS International, Inc. website at www.proiris.com. A replay of the presentation will be available approximately one hour following the live presentation and will be archived for 30 days.
About IRIS International, Inc.
IRIS International is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 2,300 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and urinary tract infections. In addition, the Company is developing molecular diagnostic tests based on its Nucleic Acid Detection Immunoassay, or NADiA(R), platform, with applications in oncology and infectious disease. For more information visit www.proiris.com.